《古今录验》续命汤治疗急性缺血性卒中患者的疗效及对炎性因子的影响研究

Study on the efficacy of life-prolonging decoction in "Gujin Luyan" in the treatment of patients with acute ischemic stroke and the effect of inflammatory factors

目的观察《古今录验》续命汤治疗急性缺血性卒中患者的疗效及炎性因子的影响。方法选择我院2016年2月~2018年2月收治的86例急性缺血性卒中患者为研究对象,按住院号尾数单双号分组,分成观察组(《古今录验》续命汤治疗)与对照组(常规西药治疗)各43例。对比两组治疗前后症状评分、神经功能采用神经功能评分(NIHSS)以及炎性因子指标[包括白介素6(IL-6)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)],对比两组治疗后总有效率,并于治疗前及治疗2个月后评价两组患者生活质量水平,采用美国波士顿健康研究所制定的生活质量评定量表(SF-36)。结果观察组治疗后的症状评分、NIHSS评分均低于对照组(P<0.05),观察组总有效率(95.35%)与对照组相比(79.07%)显著升高(P<0.05),观察组治疗后的IL-6、TNF-α、hs-CRP均低于对照组(P<0.05),治疗后观察组仅在躯体疼痛上低于对照组(P<0.05),余各维度均高于对照组(P<0.05)。结论《古今录验》续命汤治疗应用于急性缺血性卒中患者,能显著改善患者炎性因子,提升疗效,改善患者生活质量,值得临床推广。

Objective To observe the efficacy of life-prolonging decoction in "Gujin Luyan" in the treatment of patients with acute ischemic stroke and the effect of inflammatory factors. Methods 86 patients with acute ischemic stroke who were admitted to our hospital from February, 2016 to February, 2018 were selected as the study subjects. According to the even and odd number of the last one digit of the hospitalization registration number, the patients were divided into two groups: the observation group(treated with life-prolonging decoction in "Gujin Luyan") and the control group (treated with conventional Western medicine), with 43 cases in each group. The symptom scores, neurological function score (NIHSS) and inflammatory factor indicators [including interleukin-6(IL-6), tumor necrosis factor-α(TNF-α),high-sensitivity C-reactive protein (hs)-CRP)] before and after treatment were compared between the two groups. The total effective rate after treatment was compared between the two groups. The quality of life of the two groups was evaluated before treatment and two months after treatment. The Quality of Life Rating Scale (SF-36) developed by the Boston Institute of Health was used. Results The symptom scores and NIHSS in the observation group were lower than those in the control group after treatment(P<0.05). The total effective rate in the observation group (95.35%) was significantly higher than that in the control group(79.07%)(P<0.05). IL-6, TNF-α and hs-CRP in the observation group after treatment were lower than those in the control group(P<0.05). After treatment, only the physical pain in the observation group was lower than that in the control group(P<0.05), and the remaining dimensions were higher than those in the control group(P<0.05). Conclusion Life-prolonging decoction in "Gujin Luyan" in the treatment of patients with acute ischemic stroke can significantly improve patients' inflammatory factors, improve the efficacy and improve their quality of life, which is worthy of clinical promotion.